SPRO
NASDAQSpero Therapeutics Inc.
Price$1.58+0.04 (+2.27%)
01:30 PM07:45 PM
News · 26 weeks36+433%
2026-01-182026-07-12
Mix2690d
- SEC Filings8(31%)
- Insider8(31%)
- Other6(23%)
- Leadership3(12%)
- Earnings1(4%)
Latest news
25 items- SECSpero Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & RoyaltiesFinancing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt
- PRInnovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyUnder the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001)Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately US$1.1 billion, as well as tiered royalties on net salesSpero plans to initiate a Phase 2 trial for IBI355 in Q2 2027 in IgG4-related disease (IgG4-RD), a serious, chronic fibroinflammatory condition with significant treatment burden and limited therapeutic options Innovent plans to initiate a Phase 2 trial in China by early 2027 for Sjögren's disease (SjD), a
- PRSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyUnder the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments, totaling approximately US$1.1 billion, as well as tiered royalties on net salesSpero plans to initiate a Phase 2 trial for SP001 in Q2 2027 in IgG4-related disease (IgG4-RD), a serious, chronic fibroinflammatory condition with significant treatment burden and limited therapeutic options Innovent plans to initiate a Phase 2 trial in China by early 2027 for Sjögren’s disease (SjD), a chronic autoimmu
- PRAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of DirectorsLONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. He is also Chairman of three privately held companies, Micreos Group (Bilthoven, Netherlands), Secura
- PRKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per
- INSIDERDirector Deshpande Milind was granted 10,000 shares, increasing direct ownership by 11% to 101,454 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Tregoning Kathleen was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Smith Cynthia was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Vink Patrick V.J.J. was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Thomas Frank E was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Jackson Scott Thomas was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERDirector Pottage John C Jr was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- SECSEC Form 8-K filed by Spero Therapeutics Inc.8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form S-8 filed by Spero Therapeutics Inc.S-8 - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 GSK plc (LSE/NYSE:GSK) and Spero Therapeutics (NASDAQ:SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and o
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are treated annually in the US with a third of patients impacted by resistant infectionsii,iii CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative or
- PRCompass Pathways Elects Kathleen Tregoning to Board of DirectorsCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. "With two successful Phase 3 trials meeting the primary endpoint, a
- SECSEC Form 10-Q filed by Spero Therapeutics Inc.10-Q - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateNew Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway guidance into 2028 CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "We continue to make solid progress on the tebipenem HBr program alongside our licensing partner, GSK, as we pre
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- INSIDEROfficer Rajavelu Esther sold $63,352 worth of shares (25,240 units at $2.51), decreasing direct ownership by 2% to 986,851 units (SEC Form 4) to cover taxes4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- PRSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases w
- SECSEC Form DEFA14A filed by Spero Therapeutics Inc.DEFA14A - Spero Therapeutics, Inc. (0001701108) (Filer)
SPRO FAQ
7 questionsWhat does Spero Therapeutics Inc. do?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary...Where does SPRO stock trade?
Spero Therapeutics Inc. (SPRO) is listed on NASDAQ.What sector and industry is SPRO in?
Spero Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spero Therapeutics Inc. go public?
Spero Therapeutics Inc. (SPRO) completed its IPO in 2017.What are analysts saying about SPRO?
Spero Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $500.00 price target on 2024-12-20. Recent price targets range from $500.00 to $800.00.What companies are similar to SPRO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRO side-by-side with any of them on Quantisnow.How can I track SPRO on Quantisnow?
Quantisnow aggregates Spero Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRO to receive live email and push alerts on every new disclosure.